LINCOLN, Neb., Sept. 01, 2017 -- National Research Corporation (NASDAQ:NRCIA) (NASDAQ:NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per Class A share and $.60 (sixty cents) per Class B share payable Friday, October 13, 2017, to shareholders of record as of the close of business on Friday, September 29, 2017.
For more than 36 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.
Contact: Kevin R. Karas Chief Financial Officer 402-475-2525


Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Apple Turns 50: From Garage Startup to AI Crossroads 



